ALK-IN-31

• Description:

  ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor (IC50: 1135 nM) . ALK-IN-31 exhibits excellent antiproliferative activity against lung cancer H2228 cells with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation in the G0/G1 phase by affecting mitochondrial function. ALK-IN-31 exerts its anti-tumor effect by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. ALK-IN-31 can be used in the study of non-small cell lung cancer (NSCLC) [1].

• UNSPSC:

  12352005

• Target:

  Akt; Anaplastic lymphoma kinase (ALK) ; Apoptosis; mTOR

• Related Pathways:

  Apoptosis; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  O=C(C1CCCCC1)NC2=CC=CC=C2NC3=C(CSCC4)C4=NC(NC(C=C5CCC6)=CC=C5C6=O)=N3

• Molecular Formula:

  C30H33N5O2S

• Molecular Weight:

  527.68

• References & Citations:

  [1]Wang R, et al. Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity research. Bioorg Chem. 2025 Jun 15;160:108416.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [3043840-25-8]